School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, UK; Department of Cardiovascular Sciences, Katholieke University Leuven, Leuven, Belgium.
Retired Consultant Cardiothoracic Surgeon, University Hospital of Wales, Cardiff, UK.
Lancet. 2018 Aug 11;392(10146):521-530. doi: 10.1016/S0140-6736(18)31270-4. Epub 2018 Jul 17.
To use medical devices rationally, health-care professionals must base their choices of which devices to recommend for individual patients on an objective appraisal of their safety and clinical efficacy. The evidence submitted by manufacturers when seeking approval of their high-risk devices must be publicly available, including technical performance and premarket clinical studies. Giving physicians access to this information supplements the peer-reviewed scientific literature and might be essential for comparing alternative devices within any class. Interested patients should be encouraged to review the evidence for any device that has been recommended for them. The new EU law on medical devices states that the manufacturer is to prepare a summary of the evidence for any implantable or high-risk device. Defining its content, however, has been delegated to implementing legislation, which is now being considered. From a clinical perspective, it is imperative that all evidence reviewed by notified bodies and regulatory authorities is disclosed-with the exception, if justified, only of technical specifications that are considered confidential or manufacturing details that are protected as intellectual property-and public access to this evidence must be guaranteed by EU law. From ethical and other perspectives, there are no grounds for less clinical evidence being available to health-care professionals about the medical devices that they use than is already available for new pharmaceutical products. Full transparency is needed; without it, informed decisions relating to the use of new medical devices will remain impossible.
为了合理使用医疗器械,医疗保健专业人员必须根据其安全性和临床疗效的客观评估,为个别患者选择推荐使用的器械。制造商在寻求高风险器械批准时提交的证据必须公开,包括技术性能和上市前临床研究。为医生提供获取这些信息的途径,有助于补充同行评议的科学文献,对于比较同一类别内的替代器械可能是必不可少的。应鼓励感兴趣的患者查看为他们推荐的任何器械的证据。关于医疗器械的新欧盟法律规定,制造商应为任何植入式或高风险器械准备一份证据摘要。然而,对其内容的定义已被委托给正在审议的实施立法。从临床角度来看,至关重要的是,通知机构和监管机构审查的所有证据都必须公开披露——只有在有正当理由的情况下,才能排除被视为机密的技术规格和受知识产权保护的制造细节——并且必须通过欧盟法律保障公众获取这些证据。从伦理和其他角度来看,医疗保健专业人员对他们使用的医疗器械所掌握的临床证据,不应比已经可用于新的医药产品的证据更少。需要完全透明;没有它,就不可能就新的医疗器械的使用做出知情决策。